Benlysta: still 'on trial' as HGS looks to melt physician resistance
This article was originally published in Scrip
Executive Summary
Human Genome Sciences continues to struggle with convincing doctors to prescribe its new drug Benlysta (belimumab) for systemic lupus erythematosus, which first became available last March after US FDA approval. The product is in the early stages of being rolled out in several European countries by HGS and partner GlaxoSmithKline. With three full quarters under its belt in the US, HGS has pointed to steady quarter-to-quarter sales growth, but also concedes that physician adoption can take time.